Kemp Proteins, LLC
Kemp Proteins is a premier provider of customized solutions to protein-related challenges, focusing on delivering high-quality gene-to-protein services to optimize productivity and mitigate risk for clients in the life sciences. They offer a wide range of protein expression, antibody development, process development, and analytical services, supported by advanced technology and experienced scientists. Kemp Proteins is committed to building lasting relationships through quality standards, effective communication, and successful project delivery.
Industries
Nr. of Employees
small (1-50)
Kemp Proteins, LLC
5119 Pegasus Court, Suite M–P, Frederick, MD 21704
Products
Gene-to-Protein Services
Comprehensive services for gene-to-protein expression, including mammalian, E. coli, BacMam, and baculovirus systems.
Custom Monoclonal Antibody Development
Development of application-specific monoclonal antibodies using hybridoma technology, including antigen design, immunization, and high-throughput screening.
Analytical Services
Services for protein characterization, including affinity characterization, stability studies, and other analytical capabilities.
Process Development Services
Services for process discovery and optimization, including upstream and downstream process development, stable cell line development, and biomanufacturing.
High Throughput Services
High throughput screening and production services for proteins and antibodies.
Stable Cell Line Development
Development of stable cell lines for protein production and other applications.
Gene-to-Protein Services
Comprehensive services for gene-to-protein expression, including mammalian, E. coli, BacMam, and baculovirus systems.
Custom Monoclonal Antibody Development
Development of application-specific monoclonal antibodies using hybridoma technology, including antigen design, immunization, and high-throughput screening.
Analytical Services
Services for protein characterization, including affinity characterization, stability studies, and other analytical capabilities.
Process Development Services
Services for process discovery and optimization, including upstream and downstream process development, stable cell line development, and biomanufacturing.
High Throughput Services
High throughput screening and production services for proteins and antibodies.
Stable Cell Line Development
Development of stable cell lines for protein production and other applications.
Services
Consultation, gene construct design, expression, purification, and delivery of recombinant proteins for R&D and pre-GMP uses.
Expression campaigns across multiple host platforms including transient and stable mammalian, insect/baculovirus, BacMam, and bacterial systems to match target requirements.
Hybridoma generation, high-throughput screening, clone selection, initial production, characterization, and cell banking to deliver application-specific monoclonal antibodies.
Sequencing and recombinant reformatting of hybridoma-derived antibodies to provide sequence-defined recombinant production.
High-throughput, label-free affinity and kinetic characterization (ka, kd, KD), isotyping, quantification, and epitope binning to support assay and candidate selection.
Process discovery, downstream purification development, and purification scale-up using chromatography-based methods and process optimization.
Consultation, gene construct design, expression, purification, and delivery of recombinant proteins for R&D and pre-GMP uses.
Expression campaigns across multiple host platforms including transient and stable mammalian, insect/baculovirus, BacMam, and bacterial systems to match target requirements.
Hybridoma generation, high-throughput screening, clone selection, initial production, characterization, and cell banking to deliver application-specific monoclonal antibodies.
Sequencing and recombinant reformatting of hybridoma-derived antibodies to provide sequence-defined recombinant production.
High-throughput, label-free affinity and kinetic characterization (ka, kd, KD), isotyping, quantification, and epitope binning to support assay and candidate selection.
Process discovery, downstream purification development, and purification scale-up using chromatography-based methods and process optimization.
Expertise Areas
- Gene-to-protein production and optimization
- Monoclonal antibody development (hybridoma workflows)
- Hybridoma sequencing and recombinant antibody production
- Multi-platform protein expression (mammalian, baculovirus, BacMam, E. coli)
Key Technologies
- Mammalian transient and stable expression
- Baculovirus and BacMam expression systems
- Escherichia coli expression
- Electrofusion for hybridoma generation
News & Updates
Press release dated April 2, 2024, announcing a strategic partnership.
Press release dated March 5, 2024, about a subcontract for antibody development.
Press release dated February 20, 2024, about a partnership for gene to structure solutions.
Press release dated June 17, 2023, about quality system recertification.
Press release dated June 21, 2022, about a financing round.
Press release dated April 2, 2024, announcing a strategic partnership.
Press release dated March 5, 2024, about a subcontract for antibody development.
Press release dated February 20, 2024, about a partnership for gene to structure solutions.
Press release dated June 17, 2023, about quality system recertification.
Press release dated June 21, 2022, about a financing round.